Multiple Sclerosis Journal

Papers
(The H4-Index of Multiple Sclerosis Journal is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Time to move past typical syndromes in the diagnosis of multiple sclerosis84
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088. DOI: 10.1177/13524585241260564.65
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary63
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary58
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions57
Therapy challenges for NMOSD in a patient with HIV53
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity53
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes51
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient51
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series49
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No49
Sars-CoV2 infection in pregnant women with multiple sclerosis47
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO43
ACTRIMS Forum 2021 – Invited Program43
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment42
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline41
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis40
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study38
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis36
Decentralised clinical trials in multiple sclerosis research36
Thematic analysis of multiple sclerosis research by enhanced strategic diagram35
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study33
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity33
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years32
The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis32
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions32
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No31
Productivity loss among people with early multiple sclerosis: A Canadian study30
Double-negative neuromyelitis optica spectrum disorder30
Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients29
The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics29
0.029844999313354